Heat Biologics, Inc. (NASDAQ: HTBX) Starts Presentation at the 2017 Disruptive Growth Company Showcase
Heat Biologics (NASDAQ: HTBX) is a biopharmaceutical company developing novel therapies designed to activate a patient’s immune system against cancer using its CD8+ "Killer" T-cells. The company is currently enrolling patients in its phase 2 clinical trial for non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®). The company also has numerous pre-clinical programs at various stages of development. For more information, visit the company’s website at www.heatbio.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services,…







